Parenteral high‑dose ascorbate - A possible approach for the treatment of glioblastoma (Review).

ABSTRACT: For glioblastoma, the treatment with standard of care therapy comprising resection, radiation, and temozolomide results in overall survival of approximately 14-18 months after initial diagnosis. Even though several new therapy approaches are under investigation, it is difficult to achieve life prolongation and/or improvement of patient's quality of life. The aggressiveness and progression of glioblastoma is initially orchestrated by the biological complexity of its genetic phenotype and ability to respond to cancer therapy via changing its molecular patterns, thereby developing resistance. Recent clinical studies of pharmacological ascorbate have demonstrated its safety and potential efficacy in different cancer entities regarding patient's quality of life and prolongation of survival. In

SUBMITTER: Renner O 

PROVIDER: S-EPMC8104923 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature